As of Friday, January 23, Coherus Oncology, Inc.’s CHRS share price has surged by 21.70%, which has investors questioning if ...
This biotech small-cap's grown its dividend by 140% since 2016! So with an 8.3% yield, is now the time to add it to my Stocks ...
NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.
As of Friday, January 23, Jade Biosciences, Inc.’s JBIO share price has dipped by 5.64%, which has investors questioning if ...
To this day, animal testing remains one of the most controversial issues in animal rights. Activists have been fighting ...
However, I see one "dark spot" in this acquisition. Merus's operating loss was $110.4 million in Q2, up 82.4% year-over-year, which will ultimately slow Genmab's EPS growth until at least 2028.
Berger has participated in meetings (lectures, advisory boards, consultations) sponsored and compensated by pharmaceutical ...
Two-year real-world data highlight strong drug survival and effectiveness of bimekizumab in plaque psoriasis. Learn more ...
The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...
More than 140 U.S. medical organizations are advocating for the passage of a bill that would increase NIH funding for fiscal ...
Everyday Health on MSN
My eye-opening visit to a biologics manufacturing facility
Patient advocate Howard Chang’s visit to Boehringer Ingelheim’s biopharmaceutical facility revealed both how biologic ...
Hungarian biologist Tibor Gánti is an obscure figure. Now, more than a decade after his death, his ideas about how life began ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results